ATE330227T1 - Synergistische aktivierung regulatorischer elemente durch rel proteine und steroidrezeptoren - Google Patents

Synergistische aktivierung regulatorischer elemente durch rel proteine und steroidrezeptoren

Info

Publication number
ATE330227T1
ATE330227T1 AT01917078T AT01917078T ATE330227T1 AT E330227 T1 ATE330227 T1 AT E330227T1 AT 01917078 T AT01917078 T AT 01917078T AT 01917078 T AT01917078 T AT 01917078T AT E330227 T1 ATE330227 T1 AT E330227T1
Authority
AT
Austria
Prior art keywords
rel proteins
receptor
steroid receptors
rel
proteins
Prior art date
Application number
AT01917078T
Other languages
English (en)
Inventor
Christine J C Boersma
Der Saag Paulus Theodorus Van
Sacha Wissink
Der Burg Bart Van
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE330227T1 publication Critical patent/ATE330227T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AT01917078T 2000-03-08 2001-03-06 Synergistische aktivierung regulatorischer elemente durch rel proteine und steroidrezeptoren ATE330227T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00200815 2000-03-08

Publications (1)

Publication Number Publication Date
ATE330227T1 true ATE330227T1 (de) 2006-07-15

Family

ID=8171163

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01917078T ATE330227T1 (de) 2000-03-08 2001-03-06 Synergistische aktivierung regulatorischer elemente durch rel proteine und steroidrezeptoren

Country Status (13)

Country Link
US (2) US7252934B2 (de)
EP (1) EP1266227B1 (de)
JP (1) JP2003526346A (de)
CN (1) CN1411556A (de)
AT (1) ATE330227T1 (de)
AU (1) AU4419801A (de)
BR (1) BR0109010A (de)
CA (1) CA2399055A1 (de)
DE (1) DE60120656T2 (de)
ES (1) ES2266179T3 (de)
IL (1) IL150869A0 (de)
MX (1) MXPA02008102A (de)
WO (1) WO2001067110A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120656T2 (de) * 2000-03-08 2006-11-09 Akzo Nobel N.V. Synergistische aktivierung regulatorischer elemente durch rel proteine und steroidrezeptoren
TWI443337B (zh) * 2008-10-10 2014-07-01 Ct Hospitalier Universitaire Sainte Justine 用於脊柱側彎之分類及診斷的方法
EP2709711B8 (de) 2011-05-18 2017-03-22 Vatrix Medical, Inc. Beschichtete ballons zur blutgefässstabilisierung
US11077287B2 (en) 2017-10-02 2021-08-03 Anlvr, Llc Non-occluding balloon for cardiovascular drug delivery
CN111556970A (zh) * 2017-11-03 2020-08-18 奥塔哥创新有限公司 测试试剂盒和测定
WO2024206803A1 (en) * 2023-03-31 2024-10-03 The Texas A&M University System Synthetic estrogen receptor (er)-derived peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US5610174A (en) * 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
AU1873097A (en) 1996-02-14 1997-09-02 New England Deaconess Hospital Corporation Gene therapy of entothelial cells with anti-apoptotic proteins for transplantation and inflammatory conditions
CA2225187A1 (en) * 1997-07-14 1999-01-14 Universite D'ottawa/ University Of Ottawa Xaf genes and polypeptides: methods and reagents for modulating apoptosis
DE60120656T2 (de) * 2000-03-08 2006-11-09 Akzo Nobel N.V. Synergistische aktivierung regulatorischer elemente durch rel proteine und steroidrezeptoren

Also Published As

Publication number Publication date
DE60120656D1 (de) 2006-07-27
WO2001067110A1 (en) 2001-09-13
ES2266179T3 (es) 2007-03-01
US7252934B2 (en) 2007-08-07
BR0109010A (pt) 2003-06-03
EP1266227A1 (de) 2002-12-18
US20030119717A1 (en) 2003-06-26
MXPA02008102A (es) 2003-05-23
CA2399055A1 (en) 2001-09-13
DE60120656T2 (de) 2006-11-09
IL150869A0 (en) 2003-02-12
AU4419801A (en) 2001-09-17
JP2003526346A (ja) 2003-09-09
CN1411556A (zh) 2003-04-16
US20080014585A1 (en) 2008-01-17
EP1266227B1 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
Helm et al. GABAB receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element (CRE) in the hippocampus
Singh et al. Hippocampal chromatin‐modifying enzymes are pivotal for scopolamine‐induced synaptic plasticity gene expression changes and memory impairment
Liu et al. Interaction of nitric oxide, 20-HETE, and EETs during functional hyperemia in whisker barrel cortex
MA29568B1 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
Tunstall et al. Dysregulation of brain stress systems mediates compulsive alcohol drinking
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2005077122A3 (en) Compounds and compositions as lxr modulators
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
TR200100063T2 (tr) Androst-5-en-3ß,17ß-diol için farmasötik kompozisyonlar ve kullanımlar
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
WO2005030121A3 (en) Compounds, compositions and methods
Aziriova et al. Doxorubicin-induced behavioral disturbances in rats: protective effect of melatonin and captopril
Domenici et al. Permissive role of adenosine A2A receptors on metabotropic glutamate receptor 5 (mGluR5)‐mediated effects in the striatum
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
BRPI0518281A2 (pt) inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
ME02433B (me) Nitrooksiderivati prostaglandina
ATE534293T1 (de) Diarylaminhaltige verbindungen und zusammensetzungen und deren verwendung als modulatoren von c-kit-rezeptoren
NO20075245L (no) Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer
WO2007076161A3 (en) Compounds with therapeutic activity
HK1046413A1 (en) 4,5-Diaryl-3(2H)-furanone derivatives as cyclooxygenase-2 inhibitors.
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
GT200600127A (es) Producto de combinacion de o-desmetilvenlafaxina y bazedoxifeno y usos del mismo
Guan et al. Inhibition of COX‑2 and PGE2 in LPS‑stimulated RAW264. 7 cells by lonimacranthoide VI, a chlorogenic acid ester saponin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties